Disease relevance of Megestat

• Megace and no diabetes mellitus [1].
• Continued studies of Megace for the possible treatment of benign prostatic hypertrophy may be warranted since the drug appears to block several important biochemical steps which mediate the effects of androgen on the human prostate [2].
• The aim of the study was to compare efficacy and tolerability of the new aromatase inhibitor formestane (Lentaron) with megestrol acetate (Megestat) (MGA) in postmenopausal patients with advanced breast cancer [3].
• Megace for AIDS cachexia: food for thought [4].
• Megace (Bristol-Myers Squibb, Princeton, NJ) has been shown to effectively increase appetite, oral intake, and body weight [5].

High impact information on Megestat

• Nutritional status and parameters of body composition were compared in the Megace and non-Megace-treated subjects [6].
• No 3H-DHT binding to a cytosol receptor protein could be demonstrated in 4 out of 5 prostates from Megace-treated patients, whereas the presence of such a receptor was noted in 14 out of 17 untreated controls [2].
• In addition to these effects on tissue, Megace significantly decreased plasma levels of T, LH, and FSH at the end of the 4- to 25-day period; plasma prolactin levels did not change [2].
• Appetite stimulants such as Megace Oral Suspension (Bristol-Myers Squibb, Princeton, NJ) are used not so much for facilitating weight gain as for adding to the quality of life, including social and psychological well-being, by allowing patients to enjoy foods they like in a social family setting [7].
• The ventral prostates of the flutamide and RU23908 groups were similar and reduced 75% and 85% at 14 and 28 days respectively; the group receiving megace experienced prostatic regression of 49% and 65% which was significantly less of a reduction than that of the flutamide or RU23908 group [8].

Chemical compound and disease context of Megestat

• Megestrol acetate (Megace), an antiandrogen, was administered in a dosage of 80 mg daily to 6 patients with benign prostatic hypertrophy (BPH) for 4 to 25 days prior to transurethral resection of the prostate (TURP) [2].
• At the 2nd, 4th, 6th and 8th week, as the radiation dose escalated, the megace group had significantly less body weight loss than did the cisapride and control groups (P = 0.045, 0.024, 0.006, 0.003, respectively) [9].
• Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace [10].
• Comparison of Megace, Stilphostrol, Megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy [11].
• After failing to tolerate tamoxifen therapy, she received Megace, with marked improvement in her cerebellar tumor on CT scans [12].

Biological context of Megestat

• Thirteen patients with advanced pancreatic carcinoma were treated with circadian rhythm modulated infusion of 5-FUdR and Megace [13].

Associations of Megestat with other chemical compounds

• These effects of Megace on receptor concentration appear to be qualitatively quite different from those reported following castration in animals or following high-dose estrogen therapy in humans [14].
• Megestrol acetate (Megace) was used as an adjuvant treatment in 37% of patients, and no cases received initial chemotherapy [15].
• RESULTS: Forty-eight patients were enrolled in the megace group, 41 patients in the cisapride group, and 40 patients in the control group [9].
• Test drugs prior to TURP included Megace 160 mg per day, Megace 160 mg per day plus Tamoxifen 40 mg per day, Megace 160 mg a day plus ketoconazole 1200 mg per day and tamoxifen 40 mg/day [16].

Gene context of Megestat

• The mechanism of action of Megace in decreasing both cytosol and nuclear androgen receptor concentrations is unknown [14].
• We here report a 32-year old homosexual man with AIDS who had an abnormal ACTH stimulation test while taking megestrol actetate (megace) [17].

Analytical, diagnostic and therapeutic context of Megestat

• Twenty-nine patients received no postoperative treatment, 2 received chemotherapy, 3 received Megace, and 9 received radiation therapy [18].
• Two patients received radiation, three adjuvant chemotherapy, two hormonal therapy (Megace 160 mg qd), three received no therapy at all, and the treatment is not known in one case [19].
• Eighteen postmenopausal patients were randomly distributed over six groups to receive daily 90, 180 or 270 mg of MA (niagestin) orally in a cross-over study consisting of 3 periods of 6 weeks [20].

References